Sarepta Therapeutics (NASDAQ: SRPT) options priced for movement into expected FDA decision
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Wall St set for higher open as chip stocks bounce back after selloff
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- European stocks edge higher as dollar eases, oil prices fall
- Dollar rally stalls after rare FX warning from finance chiefs
- Oil extends losses on easing Middle East tension, demand concerns
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- Tesla, Blackstone, Las Vegas Sands fall premarket; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
FDA Confirms Departure of Ronald Farkas (SRPT)
September 14, 2016 10:24 AM EDTThe FDA, in an email to StreetInsider, confirmed that reviewer Ronald Farkas left the agency. Further details regarding the departure werent provided.
Rumors that Farkas took a job in the private sector surfaced after the market close on Tuesday, sending shares of DMD drug developer Sarepta Therapeutics... More
Farkas' Departure a Positive for Sarepta (SRPT) Eteplirsen Approval - Oppenheimer
September 14, 2016 6:28 AM EDTOppenheimer's Sarepta Therapeutic (NASDAQ: SRPT) analyst Michelle Gilson said their checks suggest that Ronald Farkas, MD, PhD, has indeed left the FDA; additionally, he is no longer listed in the HHS employee directory.
They view this as a positive signal for eteplirsen... More
